Marker Therapeutics wins $2.6M FDA orphan grant for MT-601 pancreatic cancer trial

Marker Therapeutics, Inc.

FDA awarded Marker Therapeutics $2.6 million under its Orphan Products Clinical Trials grants program to support a Phase 1 study of MT-601 in locally advanced unresectable pancreatic cancer.
FDA received 66 applications for the FY2026 orphan products program and selected six, including Marker's MT-601 project.
Marker plans to initiate the company-sponsored pancreatic cancer study in Q1 2027, using expanded antigen targeting, higher T-cell doses, and lymphodepletion.
Prior Baylor Phase 1/2 data in Nature Medicine showed 84.6% disease control, 7.5-month median duration of response, and 14.1-month median overall survival.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.